This study is a phase III clinical trial to evaluate the immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (multivalent conjugate) in infants aged 2 months (at least 6 weeks) and 3 months. The main objectives of the study include: 1. To evaluate the immunogenicity of the trial vaccine in infants aged 2 months (at least 6 weeks) following the corresponding immunization schedule compared to the control vaccine; 2. To evaluate the immunogenicity of the trial vaccine in infants aged 3 months following the corresponding immunization schedule compared to the 2-month group; 3. To evaluate the safety of the trial vaccine in infants aged 2 months (at least 6 weeks) and 3 months following the corresponding immunization schedule.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
seroprotection rate of 13 vaccine serotype-specific pneumococcal IgG antibodies
Timeframe: 30 days after primary immunization
13 vaccine serotype-specific pneumococcal IgG antibodies GMC
Timeframe: 30 days after primary immunization
incidence of adverse events (AE)
Timeframe: 30 minutes/0~7 days/0~30 days after each dose of vaccination
incidence of all serious adverse events (SAEs)
Timeframe: from the first dose to 6 months after primary immunization
incidence of all serious adverse events (SAEs)
Timeframe: from the first dose of vaccination to 12 months after the booster immunization